Investigational drug · Phase 3
MK-2140
Also called: Zilovertamab Vedotin, VLS-101
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
11
Any phase or sponsor naming "MK-2140"
First trial start
2022
Jan 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-2140", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Large B-Cell Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- B-cell Acute Lymphoblastic Leukemia
- Diffuse Large B-cell Lymphoma
- Burkitt Lymphoma
- Neuroblastoma
- Ewing Sarcoma
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
Approved drugs for the same conditions: Sarcoma · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-2140" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06717347 · 1,046 participants (planned) · Start Jan 27, 2025 · Primary completion Jul 2, 2029
Drug: Zilovertamab vedotin; Rituximab and 8 more · For: Diffuse Large B-Cell Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 289 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06890884 · 594 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 13, 2027
Drug: Zilovertamab vedotin; Rituximab and 7 more · For: Lymphoma, Large B-Cell, Diffuse
Sites: Mobile, Alabama; Chandler, Arizona; Glendale, Arizona · 148 sites in all
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05139017 · 290 participants (planned) · Start Jan 14, 2022 · Primary completion Sep 24, 2027
Drug: Zilovertamab vedotin; Rituximab and 4 more · For: DLBCL; Diffuse Large B-Cell Lymphoma
Sites: Glendale, Arizona; Beverly Hills, California; Walnut Creek, California · 135 sites in all
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05458297 · 189 participants (planned) · Start Jul 21, 2022 · Primary completion May 17, 2029
Drug: Zilovertamab vedotin; Nemtabrutinib · For: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma and 1 more
Sites: Anchorage, Alaska; Gilbert, Arizona; Phoenix, Arizona · 109 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05144841 · 140 participants · Start Jan 8, 2022 · Primary completion Apr 21, 2026
Drug: Zilovertamab vedotin · For: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sites: Orange, California; Whittier, California; Washington D.C., District of Columbia · 71 sites in all
- A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)Terminated
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT04504916 · 102 participants · Start Oct 7, 2020 · Primary completion Jun 12, 2023
Drug: Zilovertamab vedotin · For: Triple-negative Breast Cancer; Non-squamous Non-small-cell Lung Cancer; NSCLC and 12 more
Sites: Hollywood, Florida; Orlando, Florida; Boston, Massachusetts · 14 sites in all
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT03833180 · 91 participants · Start Mar 14, 2019 · Primary completion Dec 18, 2023
Drug: Zilovertamab vedotin · For: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma and 9 more
Sites: Duarte, California; La Jolla, California; Los Angeles, California · 14 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06395103 · 90 participants (planned) · Start Aug 16, 2024 · Primary completion Mar 31, 2029
Drug: Zilovertamab vedotin · For: B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma and 2 more
Sites: Los Angeles, California; Aurora, Colorado; New Haven, Connecticut · 71 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05406401 · 60 participants (planned) · Start Jul 14, 2022 · Primary completion Apr 26, 2029
Drug: Zilovertamab Vedotin; Cyclophosphamide and 5 more · For: Lymphoma, Large B-Cell, Diffuse (DLBCL)
Sites: Victoria, Canada; Toronto, Canada; Montreal, Canada · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1.
Kwon JA, Lee S, Kim J, et al. · MAbs 2026
- Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts.
Smith CM, Watts B, Evans K, et al. · Hemasphere 2026
- Targeting WTAP/ROR1/WNT5A-Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy.
Chen X, Pang B, Liu Y, et al. · Adv Sci (Weinh) 2026
- ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.
Raivola J, Rantanen F, Dini A, et al. · Cell Death Dis 2026
- Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Meric-Bernstam F, Gutierrez M, Sanz-Garcia E, et al. · Cancer Res Commun 2025
- A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population.
Zweers TJ, Lommerse J, van Maanen E, et al. · Clin Pharmacokinet 2024
Also in development for Diffuse Large B-Cell Lymphoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- RituxumabPhase 32 trials
Roche (Genentech) · Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
- BL-M08D1Phase 26 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Solid Tumors, Gastrointestinal Tumors, Diffuse Large B-Cell Lymphoma
- GNC-038Phase 24 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- and oxaliplatinPhase 22 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
- and prednisonePhase 22 trials
Genmab · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.